Press Releases

October 10, 2022
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor WALTHAM, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical
September 21, 2022
Paper describes key insight into integrin conformation, overcoming critical drug development challenge Company lauds Tim Springer, PhD, scientific founder of Morphic and Fu-Yang “Albert” Lin, PhD, first company employee WALTHAM, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:
Displaying 1 - 10 of 22
Scroll to Top